Capstar Special Purpose Acquisition Corp. Files for $200M IPO
by Kristi Marvin on 2020-06-11 at 2:47pm

Capstar Special Purpose Acquisition Corp. (CPSR.U), filed for a $200 million IPO this morning, and while Capstar Partners, a PE firm based in Austin Texas is the sponsor, PIMCO, the global investment management firm is part of the sponsor group as well. Additionally, Capstar Special Purpose Acquisition Corp., will be led by R. Steven Hicks, as Chairman, CEO & CFO.

Mr. Hicks founded Capstar Partners, a private investment firm focusing on small and middle market buyouts, real estate development, and public investing in the media and broadcasting, healthcare services and e-commerce industries.  However, prior to forming the PE fund, in 1996, Mr. Hicks founded Capstar Broadcasting Corporation, which became the nation’s largest radio station holding company by 1998 with 350 radio stations. Mr. Hicks will be joined by Rodrigo de la Torre, as Lead Director, having previously been the Head of Finance and Strategy for Taco Bell Global since April 2019 and previously served as Global Director of Finance and Head of M&A at Pizza Hut International from March 2016 to April 2019.

As for PIMCO, they will have a Director’s seat with Jamie Weinstein, who is currently managing director, portfolio manager and head of special situations at PIMCO, focusing on PIMCO’s opportunistic and alternative strategies within corporate credit. Furthermore, PIMCO’s Dan Degtyar, will be a Special Advisor to CPSR.U, and is currently an Executive Vice President, portfolio manager and senior analyst for PIMCO’s Global Credit Opportunity Strategy, where he focuses on credit relative value opportunities and special situations.

Having the PIMCO name on board is a nice bonus for this SPAC and will surely help with marketing. However, the terms shouldn’t give them much trouble anyway. It’s a nice fit for a first time team at 100% in trust, 24 months, and 1/2 warrant. Interestingly, they didn’t try for 1/3 warrant, especially given the PIMCO name and quality of underwriters aboard (Citigroup, UBS, BTIG).  But a 1/2 warrant makes more sense and means this deal should generate a good amount of demand.

Look for this SPAC to price ahead of the July 4th holiday week.

 

Capstar summary of terms

 

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved